CLK2: Dual specificity protein kinase CLK2
Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CLK2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Lorecivivint | Phase 3 | Biosplice Therapeutics, Inc. | Small molecule | InhibitorDual specificity protein kinase CLK2 inhibitor | 0 |
- Alzheimer disease0.48
- Neurodegenerative disease0.44
- Parkinson disease0.44
- Lysosomal storage disease0.44
- Autoimmune disorder of central nervous system0.39
- Osteoarthritis0.37
- Osteoarthritis, knee0.33
- Decreased total leukocyte count0.08
- Miyoshi myopathy0.08
- Cancer0.07
- Insulin resistance0.06
- Colorectal carcinoma0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4225, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P49760, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets